
Biofrontera Inc (NASDAQ:BFRI) shares are trading significantly higher Wednesday after the company announced it received U.S. Food and Drug Administration approval for its cGMP laboratory in Germany.
The FDA has approved Biofrontera's German laboratory as a contract lab for batch control and stability testing of Ameluz. This recognition enables significant improvements in product manufacturing efficiency, quality control and reliability of supply.